Browsing Tag
Smith+Nephew
7 posts
SN share price firms as Smith+Nephew launches $500m buyback and Cevian Capital adds to 5% activist stake
Cevian wants a breakup. Deepak Nath wants RISE to deliver. The $500m buyback is the bridge. H2 2026 is where the real test of the Smith+Nephew thesis lands.
Smith+Nephew (LSE: SN) to strengthen shoulder surgery strategy with Integrity Orthopaedics acquisition
Smith+Nephew is betting up to $450 million on Tendon Seam to reshape rotator cuff repair. Find out what this deal signals for shoulder surgery.
Smith+Nephew Q3 2025: Can the CATALYSTEM rollout and REGENETEN momentum offset VBP risks?
Smith+Nephew raises 2025 free cash flow guidance to USD 750 million as margin growth accelerates. Find out what’s driving the company’s transformation.
Smith+Nephew expands margins and cash flow—What it means for shareholders
Smith+Nephew, a global leader in medical technology, has reported a strong financial performance for 2024, highlighting steady revenue…
Smith+Nephew redefines shoulder arthroplasty with stemless implant in AETOS Shoulder System
Smith+Nephew, a global leader in medical technology (LSE: SN, NYSE: SNN), has made a significant leap in orthopaedic…
Smith+Nephew wraps up $330m acquisition of CartiHeal to expand sports medicine reach
Smith+Nephew, a global leader in medical technology, has officially completed the acquisition of CartiHeal, the developer of Agili-C,…
Smith+Nephew announces $330m acquisition of CartiHeal for innovative cartilage regeneration technology
Smith+Nephew, a global medical technology leader, today announced its definitive agreement to acquire CartiHeal, the developer of Agili-C,…